CNTA · Centessa Pharmaceuticals plc · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $0 | $15M | $0 | $6.85M | $0 | — | — | — | |
| $198.67M | $172.22M | $150.24M | $124.41M | $155.08M | — | $9.3M | $4.26M | |
| $58.02M | $50.47M | $50.81M | $53.73M | $55.2M | — | $1.14M | $790K | |
| $943K | $921K | $942K | $810K | $131K | — | $0 | $6000 | |
| -$256.69M | -$207.69M | -$201.06M | -$171.28M | -$212.26M | — | -$10.44M | -$5.05M | |
| — | -1384.61% | — | -2499.39% | — | — | — | — | |
| -$255.75M | -$206.77M | -$200.11M | -$170.47M | -$212.13M | — | -$10.44M | -$5.05M | |
| $11.31M | $11.46M | $10.09M | $9.91M | $7.28M | — | — | — | |
| $17.78M | $20.53M | $14.02M | $10.48M | — | — | — | — | |
| $860K | $2.91M | -$1.69M | -$5.43M | $2.34M | — | $155K | $105K | |
| -$249.37M | -$195.71M | -$232.91M | -$176.14M | -$216.95M | — | -$10.66M | -$5.06M | |
| $1.27M | $1.82M | $2.84M | -$25.06M | -$747K | $114K | $0 | $0 | |
| -$250.64M | -$197.53M | -$235.76M | -$151.09M | -$216.21M | — | -$10.66M | -$5.06M | |
| — | -1316.88% | — | -2204.65% | — | — | — | — | |
| -$251.31M | -$199.03M | -$233.04M | -$148.1M | -$218.39M | — | -$10.9M | -$4.65M | |
| USD/shares | -$1.78 | -$1.46 | -$2.06 | -$1.57 | -$2.31 | — | — | — |
| USD/shares | -$1.78 | -$1.46 | -$2.06 | -$1.57 | -$2.31 | — | — | — |
| shares | — | 135.72M | 114.47M | 96.18M | 93.4M | — | — | — |
| shares | — | 135.72M | 114.47M | 96.18M | 93.4M | — | — | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2020: $0 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 173 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $15,000,000 | $0 | $6,853,000 |
By Product & Service (USD)
| Component | FY2021 |
|---|---|
| Lixivaptan | $200,000,000 |